Hims & Hers Stock Plunge: What the Reversal Means

Hims & Hers Stock Sees Biggest Reversal Since 2025 Market Bottom

Shares of Hims & Hers experienced a dramatic reversal, erasing a significant rally built on a landmark partnership with drugmaker Novo Nordisk. The telehealth company’s stock surged on news it would sell branded weight-loss drugs, but the gains were wiped out by broader market fears driven by spiking oil prices, according to Sherwood News.

This whiplash is a classic case of company-specific good news getting bulldozed by macroeconomic headwinds. The reversal marks the stock's most significant intraday swing from gain to loss since the market bottom of April 2025.

A Partnership Ends a Bitter Feud

The week began on a high note for Hims & Hers Health, Inc. after it announced a surprising new partnership with Novo Nordisk A/S. The deal allows Hims to sell popular branded obesity drugs, like Wegovy, directly on its telehealth platform, a move that resolves a contentious legal battle that had created a significant overhang on the stock, as first reported by Bloomberg.

The conflict stemmed from Hims & Hers selling lower-cost, compounded versions of semaglutide, the active ingredient in Novo Nordisk's blockbuster treatments. The new pact marks a complete turnaround, positioning Hims as a legitimate distribution partner for one of the world's largest pharmaceutical companies and sending its stock soaring in premarket trading.

But that's not where the story ends.

How Macro Forces Crushed the Rally

Despite the blockbuster news, the initial optimism evaporated shortly after the market opened. Hims & Hers stock, along with many others, tumbled as Brent crude oil prices climbed above $100 per barrel, fueling inflation fears and spooking investors. The telehealth company’s shares erased an early gain of over 5% to close down more than 7%.

View on Reddit

This wasn't a reflection of the deal's quality but a stark reminder that broad market sentiment can overpower even the most positive company-specific catalysts. According to Sherwood News, it was the first time since the market-wide tumult of April 2025 that Hims saw such a dramatic intraday reversal. The market is signaling that right now, the risk of high energy costs and their impact on the economy outweighs the growth potential of a single company's strategic win.

View on Reddit

Most analysts stop at the one-day chart. The real story is what this pivot means for the company's future against giants like Amazon Pharmacy.

Key Company Metrics

Metric	Hims & Hers Health (HIMS)	Novo Nordisk A/S (NVO)
Market Cap	$5.4B	$169.6B
P/E Ratio	46.75	10.62
52-Week Range	$13.74 – $70.43	$35.85 – $82.57

FAQFrequently Asked Questions

Hims & Hers stock plunged because broader market fears, triggered by spiking oil prices and inflation concerns, overshadowed the positive news of their partnership with Novo Nordisk. The stock experienced its biggest intraday reversal since April 2025, erasing an initial gain of over 5% to close down more than 7% the same day.

Hims & Hers has partnered with Novo Nordisk to sell its branded weight-loss drugs, such as Wegovy, directly on the Hims telehealth platform. This agreement resolves a previous legal dispute between the two companies, which stemmed from Hims selling lower-cost, compounded versions of semaglutide, the active ingredient in Novo Nordisk's drugs.

Hims & Hers Health has a market cap of $5.4 billion, while Novo Nordisk A/S has a market cap of $169.6 billion. This illustrates the difference in scale between the telehealth company and the established pharmaceutical giant.

The P/E ratio for Hims & Hers Health (HIMS) is 46.75. This is significantly higher than Novo Nordisk's P/E ratio of 10.62, which could indicate different investor expectations for growth.